Alnylam Provides Preliminary Q4 Sales For Onpattro & Givlaari
Zacks Investment Research | Jan 12, 2020 10:17PM ET
Alnylam Pharmaceuticals (NASDAQ:ALNY) announced preliminary global net product revenues for Onpattro (patisiran) and Givlaari (givosiran) for the fourth quarter and updated on the products’ commercial launches. Onpattro is a first-of-its-kind RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Givlaari is the second RNAi therapeutic from the company approved by the FDA for the treatment of adults with acute hepatic porphyria (AHP).
The preliminary net product revenues for Onpattro for the fourth quarter and 2019 were about $56 million and $166 million, respectively. By the end of 2019, more than 750 patients globally received commercial Onpattro and more than 1,000 patients worldwide, including those in clinical studies and the company’s global Expanded Access Program, were being treated with the drug. The company stated that Onpattro’s new patient growth was significant in the fourth quarter in the United States and the EU, with the trend expected to continue in 2020.
Shares of the company have gained 41.9% in the past year against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.